Uniqure N.V. (QURE)

$24.87 +0.84 (3.50%)
Market Cap 1.50B
Revenue (ttm) 27.12M
Net Income (ttm) -239.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -883.33%
Debt to Equity Ratio 0.23
Volume 2,022,000
Avg Vol 2,149,212
Day's Range N/A - N/A
Shares Out 62.29M
Stochastic %K 90%
Beta 0.66
Analysts Strong Sell
Price Target $52.64

Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial t...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 20 240 6000
Address:
Paasheuvelweg 25, Amsterdam, Netherlands
MAGA1717
MAGA1717 Feb. 25 at 8:23 PM
$QURE 🤡🤡🤡👇
0 · Reply
InvestorNOR
InvestorNOR Feb. 25 at 5:00 PM
$QURE We are days, maybe hours away from hearing if FDA will honor their words to speed up rare disease treatments. AMT-130 are just sitting there, waiting to get approved with a massive data to back it up.
0 · Reply
Thinkingman91
Thinkingman91 Feb. 25 at 3:54 PM
$QURE I know nuffin
0 · Reply
Djjazzyjeff
Djjazzyjeff Feb. 25 at 2:58 PM
$QURE lol -9%
1 · Reply
stu4
stu4 Feb. 25 at 12:41 PM
$CADL yup , hahahaa, remember, TAK is a professor , NOT CEO MATERIAL…so to him , 272M is like a billion , since he never deal with Big Money , or how to run an efficient company , his Kintai ( funded by GSK) was merged to end the TAK circus of spending money with no results !!! So to your question …ya , this dolt believes it is enough. $QURE went through 2.5B, before a submission to the FDA and after that filing had to do a offering for another 200M in Nov 2025 , since Matt Kapusta pissed away the WHOLE 2.3B and still had no approval and still doesn’t ( but like TAK was never a CEO , he was an ex stock broker , ya know a shoe salesman , with an open check book to sell, no accountability to cost of sales !! ) Dilution will come again !!! With the likes of TAK and Manning
0 · Reply
Smellmahass
Smellmahass Feb. 25 at 12:38 PM
$QURE I wish we know the date they will drop fda type a meeting.
0 · Reply
Thelonius_Stonk
Thelonius_Stonk Feb. 25 at 12:10 PM
$QURE watchn again. weekly close above 26s should getting it movin
0 · Reply
Wontscalp4blow
Wontscalp4blow Feb. 25 at 11:57 AM
$NVCR $IBRX $QURE IBRX has the cure for ALL cancers. What company is actively killing gliboblastoma without Chemo? IBRX, thats who.
1 · Reply
Tdorsey1776
Tdorsey1776 Feb. 25 at 11:54 AM
$NVCR Would love to see a massive short squeeze crank up, like $IBRX and a few months ago $QURE. First new FDA approved pancreatic treatment in 3 decades!!! GLTA
2 · Reply
DARKP00L
DARKP00L Feb. 24 at 1:01 PM
$QURE 07:19 on Feb. 24 2026 Wolfe Research Initiates Coverage On uniQure with Peer Perform Rating #tradeideas
0 · Reply
Latest News on QURE
QURE INVESTOR REMINDER: uniQure N.V. Investors Have Until April 13, 2026 To Seek Lead Plaintiff Role

Feb 25, 2026, 6:00 PM EST - 8 hours ago

QURE INVESTOR REMINDER: uniQure N.V. Investors Have Until April 13, 2026 To Seek Lead Plaintiff Role

uniQure to Announce 2025 Financial Results

Feb 23, 2026, 7:05 AM EST - 2 days ago

uniQure to Announce 2025 Financial Results

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure Lawsuit - QURE

Feb 19, 2026, 10:00 AM EST - 6 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure Lawsuit - QURE

UniQure N.V. (QURE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Feb 18, 2026, 10:06 AM EST - 7 days ago

UniQure N.V. (QURE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large Losses in uniQure N.V.

Feb 17, 2026, 8:16 AM EST - 8 days ago

UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large Losses in uniQure N.V.

Diamond Hill International Strategy Q4 2025 Portfolio Review

Feb 17, 2026, 2:14 AM EST - 8 days ago

Diamond Hill International Strategy Q4 2025 Portfolio Review

BABA ICLR NWG

Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch

Feb 6, 2026, 1:58 PM EST - 19 days ago

Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch

uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

Feb 6, 2026, 7:05 AM EST - 19 days ago

uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

Alger Small Cap Focus Fund Q4 2025 Portfolio Update

Jan 29, 2026, 1:22 PM EST - 27 days ago

Alger Small Cap Focus Fund Q4 2025 Portfolio Update

EXAS GH NBIS NTRA STVN

uniQure Announces Type A Meeting Scheduled with FDA

Jan 9, 2026, 7:05 AM EST - 6 weeks ago

uniQure Announces Type A Meeting Scheduled with FDA

uniQure: Now What?

Jan 8, 2026, 3:36 PM EST - 6 weeks ago

uniQure: Now What?

What's Going On With uniQure Stock On Tuesday?

Dec 16, 2025, 12:17 PM EST - 2 months ago

What's Going On With uniQure Stock On Tuesday?

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

Dec 7, 2025, 12:01 PM EST - 2 months ago

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

Why uniQure Stock Is Trading Lower After FDA Meeting Update

Dec 4, 2025, 1:30 PM EST - 2 months ago

Why uniQure Stock Is Trading Lower After FDA Meeting Update

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

Dec 4, 2025, 7:05 AM EST - 2 months ago

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

Diamond Hill International Strategy Q3 2025 Performance Review

Nov 17, 2025, 8:59 AM EST - 3 months ago

Diamond Hill International Strategy Q3 2025 Performance Review

BABA HDB TSM

uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QURE

Nov 14, 2025, 4:17 AM EST - 3 months ago

uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QURE

QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm

Nov 12, 2025, 10:00 AM EST - 3 months ago

QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm

From Setback To Surge: UniQure's Huntington's Hope Is Poised For Upside

Nov 10, 2025, 12:44 PM EST - 3 months ago

From Setback To Surge: UniQure's Huntington's Hope Is Poised For Upside

uniQure N.V. (QURE) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 11:11 AM EST - 3 months ago

uniQure N.V. (QURE) Q3 2025 Earnings Call Transcript

uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 10, 2025, 7:05 AM EST - 3 months ago

uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update

uniQure to Announce Third Quarter 2025 Financial Results

Nov 6, 2025, 7:05 AM EST - 3 months ago

uniQure to Announce Third Quarter 2025 Financial Results

UniQure Shares Drop After FDA Shifts Stance On Huntington's Gene Therapy Data

Nov 3, 2025, 1:04 PM EST - 4 months ago

UniQure Shares Drop After FDA Shifts Stance On Huntington's Gene Therapy Data

uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QURE

Nov 3, 2025, 10:01 AM EST - 4 months ago

uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QURE

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 4 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

UniQure Stock Plummets 67% on Potential FDA Decision. Here's Why.

Nov 3, 2025, 8:11 AM EST - 4 months ago

UniQure Stock Plummets 67% on Potential FDA Decision. Here's Why.

FDA says clinical data for UniQure's Huntington's disease therapy not adequate

Nov 3, 2025, 7:18 AM EST - 4 months ago

FDA says clinical data for UniQure's Huntington's disease therapy not adequate

uniQure: 3-Year Huntington's Data Move AMT-130 From 'Promising' To 'Probable' (Rating Upgrade)

Oct 28, 2025, 1:55 PM EDT - 4 months ago

uniQure: 3-Year Huntington's Data Move AMT-130 From 'Promising' To 'Probable' (Rating Upgrade)

uniQure: Further Upside Likely As The Opportunity Becomes Better Understood

Oct 8, 2025, 3:33 PM EDT - 5 months ago

uniQure: Further Upside Likely As The Opportunity Becomes Better Understood

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Sep 29, 2025, 4:05 PM EDT - 5 months ago

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

uniQure Announces Pricing of Upsized $300 Million Public Offering

Sep 25, 2025, 11:38 PM EDT - 5 months ago

uniQure Announces Pricing of Upsized $300 Million Public Offering

UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street

Sep 25, 2025, 8:37 AM EDT - 5 months ago

UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street

uniQure Stock Jumps On Positive News, But Risks Remain

Sep 25, 2025, 7:23 AM EDT - 5 months ago

uniQure Stock Jumps On Positive News, But Risks Remain

UniQure: How QURE Stock Rises 10x To $500?

Sep 25, 2025, 6:20 AM EDT - 5 months ago

UniQure: How QURE Stock Rises 10x To $500?

Here's why biotech UniQure's stock just tripled, and brought ClearPoint shares up with it

Sep 24, 2025, 4:37 PM EDT - 5 months ago

Here's why biotech UniQure's stock just tripled, and brought ClearPoint shares up with it

uniQure: Positive 3-Year AMT-130 Data Leads To Pre-BLA FDA Meeting And Beyond

Sep 24, 2025, 4:24 PM EDT - 5 months ago

uniQure: Positive 3-Year AMT-130 Data Leads To Pre-BLA FDA Meeting And Beyond

uniQure Announces $200 Million Proposed Public Offering

Sep 24, 2025, 4:06 PM EDT - 5 months ago

uniQure Announces $200 Million Proposed Public Offering

uniQure N.V. - Special Call

Sep 24, 2025, 1:03 PM EDT - 5 months ago

uniQure N.V. - Special Call

MAGA1717
MAGA1717 Feb. 25 at 8:23 PM
$QURE 🤡🤡🤡👇
0 · Reply
InvestorNOR
InvestorNOR Feb. 25 at 5:00 PM
$QURE We are days, maybe hours away from hearing if FDA will honor their words to speed up rare disease treatments. AMT-130 are just sitting there, waiting to get approved with a massive data to back it up.
0 · Reply
Thinkingman91
Thinkingman91 Feb. 25 at 3:54 PM
$QURE I know nuffin
0 · Reply
Djjazzyjeff
Djjazzyjeff Feb. 25 at 2:58 PM
$QURE lol -9%
1 · Reply
stu4
stu4 Feb. 25 at 12:41 PM
$CADL yup , hahahaa, remember, TAK is a professor , NOT CEO MATERIAL…so to him , 272M is like a billion , since he never deal with Big Money , or how to run an efficient company , his Kintai ( funded by GSK) was merged to end the TAK circus of spending money with no results !!! So to your question …ya , this dolt believes it is enough. $QURE went through 2.5B, before a submission to the FDA and after that filing had to do a offering for another 200M in Nov 2025 , since Matt Kapusta pissed away the WHOLE 2.3B and still had no approval and still doesn’t ( but like TAK was never a CEO , he was an ex stock broker , ya know a shoe salesman , with an open check book to sell, no accountability to cost of sales !! ) Dilution will come again !!! With the likes of TAK and Manning
0 · Reply
Smellmahass
Smellmahass Feb. 25 at 12:38 PM
$QURE I wish we know the date they will drop fda type a meeting.
0 · Reply
Thelonius_Stonk
Thelonius_Stonk Feb. 25 at 12:10 PM
$QURE watchn again. weekly close above 26s should getting it movin
0 · Reply
Wontscalp4blow
Wontscalp4blow Feb. 25 at 11:57 AM
$NVCR $IBRX $QURE IBRX has the cure for ALL cancers. What company is actively killing gliboblastoma without Chemo? IBRX, thats who.
1 · Reply
Tdorsey1776
Tdorsey1776 Feb. 25 at 11:54 AM
$NVCR Would love to see a massive short squeeze crank up, like $IBRX and a few months ago $QURE. First new FDA approved pancreatic treatment in 3 decades!!! GLTA
2 · Reply
DARKP00L
DARKP00L Feb. 24 at 1:01 PM
$QURE 07:19 on Feb. 24 2026 Wolfe Research Initiates Coverage On uniQure with Peer Perform Rating #tradeideas
0 · Reply
stu4
stu4 Feb. 23 at 8:16 PM
$QURE called the Matt Kapu-shit lies being told to his old broker friends ….He went to Trump University.
0 · Reply
JFais
JFais Feb. 21 at 1:17 PM
$XBI- A few weekend discussion points from Chat: $QURE- keep in mind even if allowed to refile, uphill battle for HD GTx program with this FDA & especially VP (review ≠ approval) $CMPS- magic mushrooms finally making it to the big time? Highly stat sig in two phase 3 trials with possible Kennedy backing, $150M secondary & BLA filing in Q4 $AKBA- seems a few people dumpster diving in this "Black Sheep" name from @TDMInvest. $1B TAM for Vasfeo, even $300M in sales would put valuation at 1x
1 · Reply
RinseX3
RinseX3 Feb. 21 at 10:53 AM
$QURE Some elements on the timeline that make one hopeful for good news on Monday. Just fun speculation ofc and we'll know soon enough either way. 1/9 Company announces a date is set for Type A meeting. 1/21 Help4HD website posts a letter from uniQure Executive Director of Global Patient Advocacy sent on 1/20 thanking the HD community and stating they will include a community representative at the Type A meeting. 1/27 another post on Help4HD indicates that on 1/22 community members handed 2 petitions to the FDA. This is pure speculation, but what is the best time to hand the petitions to the FDA? The day of the Type A meeting. 1/22 unusual AH activity for no obvious reason with 122K shares traded by 9pm at >10%. 1/23 stock gaps up and 1M shares traded in 1h at >10% for no obvious reason. 4M shares on the day. If the Type A meeting indeed took place on 1/22, trading pattern could suggest a positive outcome with minutes likely on Mon. GLTA!
1 · Reply
JFais
JFais Feb. 20 at 9:54 PM
Updated after today's trades + raised cash for taxes A few good years in biotech has its consequences $XBI (thankful to have gains at all 🙏) Also agree with Jesse Livermore (when $$ in hand, becomes more real/concrete) Rationale of latest swaps= reduce regulatory risk $QURE
1 · Reply
LunarPanda1
LunarPanda1 Feb. 19 at 7:48 PM
:; $NEON $LAC $QURE $AMD ||
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 19 at 6:17 PM
$QURE RSI: 50.18, MACD: -0.3279 Vol: 1.73, MA20: 24.14, MA50: 23.30 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
stu4
stu4 Feb. 19 at 5:03 PM
$QURE sec and shorts read this media since the Roaring Kitty ruined the hedge funds !!
0 · Reply
MAGA1717
MAGA1717 Feb. 19 at 3:07 PM
$QURE 🤡🤡🤡👇 you know what to do
0 · Reply
GTMONeyjj
GTMONeyjj Feb. 19 at 1:53 PM
$QURE Someone just scooped up 9,000 shares in one go. 9,000 shares is a bit of a gray area—too many for a typical retail investor, but too few for an institution.
0 · Reply
stu4
stu4 Feb. 19 at 1:25 PM
$QURE looks like MATT’s ex stock broker friends , still playing this with his calls of “ secrets “
0 · Reply
vu_jade
vu_jade Feb. 19 at 4:14 AM
$QURE Hello FDA .. my old friend…
0 · Reply